slides · global inventory
27 Cost Of Inaction
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 31,900
Current window 22,231-22,260
Pages 1,064
Rows per page 30
Loop
22,231-22,260 of 31,900
09
The slide uses a structured table to highlight gaps in current treatment standards.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Uses a 'case study' framework to validate the proposed strategy by drawing a parallel to an existing successful drug (Osimertinib).Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
09
The slide uses a structured table to contrast two distinct patient populations (ALK+ vs ROS1+) across three lines of therapy (1L, 2L, 3L+).Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Uses a 'cite_precedent' framework to validate the strategy by comparing it to the established success of Osimertinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
03
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
04
The slide uses a visual layout to associate each executive with specific past pharmaceutical successes.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
05
The slide uses a table-like structure to represent a clinical trial roadmap, incorporating regulatory designations and partner logos.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
06
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Includes a biological pathway diagram and a dose-response curve showing target validation.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide presents experimental evidence (Western blot) supporting the mechanism of action for NXP800 in ARID1a-deficient cancer cells.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
Includes two line charts showing tumor volume reduction over time and a table showing patient incidence for target indications.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
Includes a patient-derived xenograft (PDX) study methodology diagram and a line chart showing tumor volume over time.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
11
The slide presents three separate line charts showing tumor growth inhibition over time for different cell lines (RL95-2, KLE, SNG-M).Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
12
The slide uses a patient selection strategy based on ARID1a mutation status.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
13
The slide uses a split-column layout to contrast two phases of a clinical trial.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
07
P3 Health Partners | Investor Conference Presentation Deck | 19 slidesP3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
PMPM stands for Per Member Per Month.P3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
09
The chart shows a clear downward trend in medical costs for all cohorts compared to the rising benchmark.P3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
10
The chart uses dashed lines with markers for three distinct metrics. A callout box provides the key takeaway comparing internal performance to industry trends.P3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
12
Pathward Financial | Results Presentation Deck | 34 slidesPathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
13
Pathward Financial | Results Presentation Deck | 34 slidesPathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
14
Includes adjustments for one-time items and 1st quarter earnings breakdowns.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
15
Includes a disclaimer note regarding share repurchases.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
16
Pathward Financial | Results Presentation Deck | 34 slidesPathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
17
Includes a detailed income statement table and bulleted commentary on revenue and expense drivers.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
07
South Plains Financial | Results Presentation Deck | 25 slidesSouth Plains Financial | Results Presentation Deck | 25 slides · South Plains Financial
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
08
The slide includes a footnote defining 'major metropolitan markets' as Dallas, Houston, and El Paso.South Plains Financial | Results Presentation Deck | 25 slides · South Plains Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
09
HFI stands for Held-for-Investment.South Plains Financial | Results Presentation Deck | 25 slides · South Plains Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit